SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-18-012395
Filing Date
2018-05-09
Accepted
2018-05-09 16:07:09
Documents
73
Period of Report
2018-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q akba-10q_20180331.htm 10-Q 1904449
2 EX-31.1 akba-ex311_6.htm EX-31.1 17684
3 EX-31.2 akba-ex312_10.htm EX-31.2 17263
4 EX-32.1 akba-ex321_7.htm EX-32.1 12208
5 EX-99.1 akba-ex991_348.htm EX-99.1 87111
6 GRAPHIC g201805091736204392911.jpg GRAPHIC 4985
  Complete submission text file 0001564590-18-012395.txt   8529728

Data Files

Seq Description Document Type Size
7 XBRL INSTANCE DOCUMENT akba-20180331.xml EX-101.INS 2003062
8 XBRL TAXONOMY EXTENSION SCHEMA akba-20180331.xsd EX-101.SCH 69012
9 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE akba-20180331_cal.xml EX-101.CAL 53676
10 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE akba-20180331_def.xml EX-101.DEF 245377
11 XBRL TAXONOMY EXTENSION LABEL LINKBASE akba-20180331_lab.xml EX-101.LAB 448029
12 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE akba-20180331_pre.xml EX-101.PRE 387479
Mailing Address 245 FIRST STREET CAMBRIDGE MA 02142
Business Address 245 FIRST STREET CAMBRIDGE MA 02142 617-871-2098
Akebia Therapeutics, Inc. (Filer) CIK: 0001517022 (see all company filings)

IRS No.: 208756903 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36352 | Film No.: 18818294
SIC: 2834 Pharmaceutical Preparations